The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength

Wei Yao, Zhiqiang Cheng, Kurt J. Koester, Joel W. Ager, Mehdi Balooch, Aaron Pham, Solomon Chefo, Cheryl Busse, Robert O. Ritchie, Nancy E Lane

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this study, 18-month Fischer 344 rats were ovariectomized and treated with a single dose of risedronate (intravenous, iv, 500 μg), zoledronic acid (iv, 100 μg) or continuous raloxifene (2 mg/kg, po, 3×/week). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle X-ray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen-deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene.

Original languageEnglish (US)
Pages (from-to)804-812
Number of pages9
JournalBone
Volume41
Issue number5
DOIs
StatePublished - Nov 2007

Fingerprint

Physiologic Calcification
Diphosphonates
Estrogens
Bone and Bones
zoledronic acid
Minerals
Compressive Strength
X-Ray Microtomography
Bone Remodeling
Bone Fractures
Inbred F344 Rats
Bone Density
Therapeutics
X-Rays
Incidence
Raloxifene Hydrochloride
Cancellous Bone

Keywords

  • Bone mineralization
  • Compression strength
  • Intravenous bisphosphonates
  • OVX
  • Rat

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. / Yao, Wei; Cheng, Zhiqiang; Koester, Kurt J.; Ager, Joel W.; Balooch, Mehdi; Pham, Aaron; Chefo, Solomon; Busse, Cheryl; Ritchie, Robert O.; Lane, Nancy E.

In: Bone, Vol. 41, No. 5, 11.2007, p. 804-812.

Research output: Contribution to journalArticle

Yao, Wei ; Cheng, Zhiqiang ; Koester, Kurt J. ; Ager, Joel W. ; Balooch, Mehdi ; Pham, Aaron ; Chefo, Solomon ; Busse, Cheryl ; Ritchie, Robert O. ; Lane, Nancy E. / The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. In: Bone. 2007 ; Vol. 41, No. 5. pp. 804-812.
@article{70ec7cc96e4b4a569f66021ba8c16b32,
title = "The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength",
abstract = "The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this study, 18-month Fischer 344 rats were ovariectomized and treated with a single dose of risedronate (intravenous, iv, 500 μg), zoledronic acid (iv, 100 μg) or continuous raloxifene (2 mg/kg, po, 3×/week). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle X-ray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen-deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene.",
keywords = "Bone mineralization, Compression strength, Intravenous bisphosphonates, OVX, Rat",
author = "Wei Yao and Zhiqiang Cheng and Koester, {Kurt J.} and Ager, {Joel W.} and Mehdi Balooch and Aaron Pham and Solomon Chefo and Cheryl Busse and Ritchie, {Robert O.} and Lane, {Nancy E}",
year = "2007",
month = "11",
doi = "10.1016/j.bone.2007.06.021",
language = "English (US)",
volume = "41",
pages = "804--812",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength

AU - Yao, Wei

AU - Cheng, Zhiqiang

AU - Koester, Kurt J.

AU - Ager, Joel W.

AU - Balooch, Mehdi

AU - Pham, Aaron

AU - Chefo, Solomon

AU - Busse, Cheryl

AU - Ritchie, Robert O.

AU - Lane, Nancy E

PY - 2007/11

Y1 - 2007/11

N2 - The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this study, 18-month Fischer 344 rats were ovariectomized and treated with a single dose of risedronate (intravenous, iv, 500 μg), zoledronic acid (iv, 100 μg) or continuous raloxifene (2 mg/kg, po, 3×/week). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle X-ray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen-deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene.

AB - The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this study, 18-month Fischer 344 rats were ovariectomized and treated with a single dose of risedronate (intravenous, iv, 500 μg), zoledronic acid (iv, 100 μg) or continuous raloxifene (2 mg/kg, po, 3×/week). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle X-ray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen-deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene.

KW - Bone mineralization

KW - Compression strength

KW - Intravenous bisphosphonates

KW - OVX

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=35348820573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348820573&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2007.06.021

DO - 10.1016/j.bone.2007.06.021

M3 - Article

C2 - 17825637

AN - SCOPUS:35348820573

VL - 41

SP - 804

EP - 812

JO - Bone

JF - Bone

SN - 8756-3282

IS - 5

ER -